Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1999-04-27
2000-08-15
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514274, 514812, A61K 31513, A61K 317068
Patent
active
061037036
ABSTRACT:
Disclosed herein is a method for reducing stimulant dependencies in mammals that involves administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, such as CDP-choline.
REFERENCES:
Agnoli, A. et al., "Efficacy of CDP-choline in chronic cerebral vascular diseases (CCVD)," Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine 30:305-315 (1985).
Babb, S. M. et al., "Differential effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy," Psychopharmacology 127:88-91 (1996).
Boudouresques, B.A., "Therapeutic conduct in the light of cerebral vascular accident and the use of CDP-choline," International Symposium: Brain Suffering and Precursors of Phospholipids pp. 1-12 (1980).
Brown et al., "CNS complications of cocaine abuse: Prevalence, Pathophysiology, and Neuroradiology," Am. J. Roentgenol. 159:137-147 (1992).
Centrone, G. et al., "Use of citicoline in high dosages in acute cerebrovascular disease," Minerva Med. 77:371-373 (1986).
Chang et al., "Neurochemical alterations in asymptomatic abstinent cocaine users: A proton magnetic resonance spectroscopy study," Society of Biological Psychiatry 42:1105-1114 (1997).
Christensen et al., "Abnormal cerebral metabolism in polydrug abusers during early withdrawal: A .sup.31 P MR Spectroscopy Study," Magnetic Resonance in Medicine 35:658-663 (1996).
Citicoline Sodium (CDP-Choline), investigator's brochure, revised: Apr. 1994 by Interneuron Pharmaceuticals, Inc.
Cohen et al., "Decreased brain choline uptake in older adults," JAMA 274:902-907 (1995).
English et al., "Elevated frontal lobe cytosolic choline levels in minimal or mild AIDS dementia complex patients: A proton magnetic resonance spectroscopy study," Society of Biological Psychiatry 41:500-502 (1997).
Gallai, V. et al., "Study of the P300 and cerebral maps in subjects with multi-infarct dementia treated with cytidine," Psychopharmacology 103:1-5 (1991).
Galletti, P. et al., "Biochemical rationale for the use of CDP-choline in traumatic brain injury: Pharmacokinetics of the orally adminstered drug," J. Neurol. Sci. 103:S19-S25 (1991).
Hoff et al., "Effects of crack cocaine on neurocognitive function," Psychiatry Research 60:167-176 (1996).
Jacobs et al., "Cocaine abuse: Neurovascular complications," Radiology 170:223-227 (1989).
Kaufman, M.J. et al., "Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography," JAMA 279:376-380 (1998).
Kreek et al., "Opiate and cocaine addictions: Challenge for pharmacotherapies," Pharmacol. Biochem. Behav. 57:551-569 (1997).
Levin, J.M. et al., "Improved regional cerebral blood flow in chronic cocaine polydrug users treated with buprenorphine," J. Nucl. Med. 36:1211-1215 (1995).
London et al., Cerebral glucose utilization in human herion addicts: Case reports from a positron emission tomographic study, Research Communications in Substances of Abuse 10:141-144 (1989).
Maas, LC. et al., "Functional magnetic resonance imaging of human brain activation during cue-induced craving," Am. J. Psychiatry 155:124-126 (1998).
McCance, "Overview of potential treatment medications for cocaine dependence," NIDA Res. Monogr., 175:36-72 (1997).
Moglia, A. et al., "Citicoline in patients with chronic cerebrovascular diseases (CCVD)," Curr. Ther. Res. 36:309-313 (1984).
O'Rouke, M.M. et al., "Effect of chronic cocaine exposure on carotid artery reactivity in neonatal rabbits," Life Sciences 36:309-313 (1996).
Petrson et al., "Neurovascular Complications of Cocaine Abuse," J. Neuropsychiatry Clin. Neurosci., 3:143-149 (1991).
Saligaut, C. et al., "Circling behavior in rats with unilateral lesions of the nigrostriatum induced by hydroxydopamine: Changes induced by oral administration of cytidine-5'-Diphosphocholine," Neuropharmacology, 26:1315-1319 (1987).
Salvadorini, F. et al., "Clinical evaluation of CDP-choline (NICHOLIN.RTM.): Efficacy as antidepressant treatment," Curr. Ther. Res. 18:513-520 (1975).
Secades, J.J. et al., "CDP-choline: Pharmacological and clinical review," Methods Find. Exp. Clin. Pharmacol. 17:1-54 (1995).
Self, et al., "Opposite modulation of cocaine-seeking behavior by D.sub.1 - and D.sub.2 -like dopamine receptor agonists," Science 271:1586-1589 (1996).
Sholar, M.B. et al., "Concurrent pharmacokinetic analysis of plasma cocaine and adrenocorticotropic hormone in men," Journal of Clinical Endocrinology and Metabolism 83:966-968 (1998).
Tazaki, Y. Et al., Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study, Stroke 19:211-216 (1988).
Teoh, S.K. et al., "Acute interactions of buprenorphine with intravenous cocaine and morphine: An investigational new drug phase I safety evaluation," J. Clin. Psychopharmacology 13:87-99 (1993).
Warner et al., "Pharmacotherapy for opioid and cocaine abuse," Med. Clin. North Am., 81:909-928 (1997).
Weiss, G. B., Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline, Life Sci., 56:637-660 (1995).
Lukas Scott
Renshaw Perry F.
Spivack Phyllis G.
The McLean Hospital Corporation
LandOfFree
Cytidine-containing and cytosine-containing compounds as treatme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytidine-containing and cytosine-containing compounds as treatme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytidine-containing and cytosine-containing compounds as treatme will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2006933